241 related articles for article (PubMed ID: 35031693)
1. The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.
Mahajan S; Dandapath I; Garg A; Sharma MC; Suri V; Sarkar C
Lab Invest; 2022 Jul; 102(7):670-681. PubMed ID: 35031693
[TBL] [Abstract][Full Text] [Related]
2. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA
Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma.
Zhang H; Ma XJ; Xiang XP; Wang QY; Tang JL; Yu XY; Xu JH
Curr Oncol; 2023 Feb; 30(2):2405-2416. PubMed ID: 36826144
[TBL] [Abstract][Full Text] [Related]
4. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.
Koelsche C; Sahm F; Wöhrer A; Jeibmann A; Schittenhelm J; Kohlhof P; Preusser M; Romeike B; Dohmen-Scheufler H; Hartmann C; Mittelbronn M; Becker A; von Deimling A; Capper D
Brain Pathol; 2014 Apr; 24(3):221-9. PubMed ID: 24345274
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidates for Immune Checkpoint Blockade?
Mahajan S; Singh J; Dandapath I; Jha P; Chaturvedi S; Ahuja A; Bhardwaj M; Saran R; Garg A; Sharma MC; Manjunath N; Suri A; Sarkar C; Suri V
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):84-95. PubMed ID: 38158760
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
[TBL] [Abstract][Full Text] [Related]
8. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
[TBL] [Abstract][Full Text] [Related]
9. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
[TBL] [Abstract][Full Text] [Related]
10. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.
Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y
Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018
[TBL] [Abstract][Full Text] [Related]
11. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY
J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
[TBL] [Abstract][Full Text] [Related]
14. Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins?
Alexandrescu S; Korshunov A; Lai SH; Dabiri S; Patil S; Li R; Shih CS; Bonnin JM; Baker JA; Du E; Scharnhorst DW; Samuel D; Ellison DW; Perry A
Brain Pathol; 2016 Mar; 26(2):215-23. PubMed ID: 26238627
[TBL] [Abstract][Full Text] [Related]
15. Cerebellar pleomorphic xanthoastrocytoma in the setting of neurofibromatosis type-I: Does it portend a different prognosis? A case report and systematic review.
Mathkour M; Banerjee S; Werner C; Hanna J; Abou-Al-Shaar H; Dindial R; Scullen T; Boehm L; Tubbs RS; Ware ML
Clin Neurol Neurosurg; 2021 Jan; 200():106346. PubMed ID: 33160715
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
Kaulich K; Blaschke B; Nümann A; von Deimling A; Wiestler OD; Weber RG; Reifenberger G
J Neuropathol Exp Neurol; 2002 Dec; 61(12):1092-9. PubMed ID: 12484572
[TBL] [Abstract][Full Text] [Related]
17. Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.
Ebrahimi A; Korshunov A; Reifenberger G; Capper D; Felsberg J; Trisolini E; Pollo B; Calatozzolo C; Prinz M; Staszewski O; Schweizer L; Schittenhelm J; Harter PN; Paulus W; Thomas C; Kohlhof-Meinecke P; Seiz-Rosenhagen M; Milde T; Casalini BM; Suwala A; Wefers AK; Reinhardt A; Sievers P; Kramm CM; Etminam N; Unterberg A; Wick W; Herold-Mende C; Sturm D; Pfister SM; Sill M; Jones DTW; Schrimpf D; Reuss DE; Aldape K; Abdullaev Z; Sahm F; von Deimling A; Stichel D
Acta Neuropathol Commun; 2022 Jan; 10(1):5. PubMed ID: 35012690
[TBL] [Abstract][Full Text] [Related]
18. Impact of Grade on Survival in Pleomorphic Xanthoastrocytoma and Low Prevalence of BRAF V600E Mutation.
Gandham EJ; Goyal-Honavar A; Beno D; Pai R; Balakrishan R; Jasper A; Gowri M; Moorthy RK; Chacko AG; Chacko G
World Neurosurg; 2022 Aug; 164():e922-e928. PubMed ID: 35618235
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.
Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H
Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
Purkait S; Bansal S; Malgulwar PB
Neuropathology; 2019 Feb; 39(1):64-67. PubMed ID: 30557911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
